The MRC Confidence in Concept (CIC) at UCL Fund 2016
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Betts CA
(2021)
Dystrophin involvement in peripheral circadian SRF signalling.
in Life science alliance
Chiu YJ
(2020)
The Effect of Solvent Vapor Annealing on Drug-Loaded Electrospun Polymer Fibers.
in Pharmaceutics
Cozmescu AC
(2021)
Gene therapies targeting the liver.
in Journal of hepatology
Gong G
(2023)
A small-molecule PI3Ka activator for cardioprotection and neuroregeneration
in Nature
Hendow EK
(2020)
Microporous Biodegradable Films Promote Therapeutic Angiogenesis.
in Advanced healthcare materials
Karda R
(2019)
Production of lentiviral vectors using novel, enzymatically produced, linear DNA.
in Gene therapy
Lorvellec M
(2020)
An In Vitro Whole-Organ Liver Engineering for Testing of Genetic Therapies.
in iScience
Meng J
(2020)
Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells.
in International journal of molecular sciences
Moore M
(2018)
Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?
in Cell and Gene Therapy Insights
Ng J
(2021)
Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.
in Science translational medicine
Qiu Y
(2022)
On-demand cell-autonomous gene therapy for brain circuit disorders.
in Science (New York, N.Y.)
Riccio F
(2019)
Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases
in Biology Open
Roddie C
(2017)
Immunotherapy for transplantation-associated viral infections.
in The Journal of clinical investigation
Rossignoli G
(2021)
Aromatic l-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies.
in Brain : a journal of neurology
Shafat MS
(2020)
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
in Frontiers in immunology
Xiong S
(2021)
Sponge-like Chitosan Based Porous Monolith for Uraemic Toxins Sorption.
in Nanomaterials (Basel, Switzerland)
Yilmaz BS
(2020)
Gene therapy for inherited metabolic diseases.
in Journal of mother and child
| Description | Apollo Tx - Trevor Askwith - mesothelioma |
| Amount | £150,000 (GBP) |
| Organisation | Apollo Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2020 |
| Description | BRC Cardiovascular Diseases Theme - Richard Angell |
| Amount | £29,536 (GBP) |
| Organisation | University College Hospital |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | |
| Description | CRUK Pioneer Award - Bart Vanhaesebroeck - PI3K |
| Amount | £200,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2021 |
| Description | Developing novel gene therapy technology for treatment of glycine encephalopathy |
| Amount | £365,837 (GBP) |
| Funding ID | 210774/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 08/2020 |
| Description | How do the class I PI3K isoforms contribute to reperfusion injury and ischaemic preconditioning? |
| Amount | £198,067 (GBP) |
| Funding ID | PG/16/85/32471 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | LMB/AZ Blue Sky Fund - Angel/Vanhaesebroeck |
| Amount | £200,000 (GBP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | MRC Joint Global health Trials Scheme - Klein - preterm birth risk |
| Amount | £2,540,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2024 |
| Description | Medcity Collaborate 2 Innovate - Counsell - Lenti viral Technology |
| Amount | £99,926 (GBP) |
| Organisation | MedCity |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2020 |
| Description | NIHR GOSH BRC - Nigel Klein - determining preterm birth risk |
| Amount | £14,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 04/2020 |
| Description | Proximity-2-Discovery - Richard Angell |
| Amount | £24,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | UCL HEIF - Counsell - Lenti Viral technology |
| Amount | £20,000 (GBP) |
| Organisation | Higher Education Innovation Funding (HEIF) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 04/2019 |
| Description | UCL Knowledge and Innovation Fund - Richard Angell |
| Amount | £24,000 (GBP) |
| Organisation | Higher Education Innovation Funding (HEIF) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | UCL Tech Fund - Counsell - Lentiviral development for DMD |
| Amount | £2,500,000 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2026 |
| Description | UCL Technology Fund - Counsell -Lenti viral technology |
| Amount | £150,000 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | Validating the safety and efficacy of novel lentiviral vector technology in stem cell therapy for Duchenne Muscular Dystrophy |
| Amount | £330,000 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 01/2023 |
| Description | Wellcome Trust Innovator Award -Claire Roddie T-cell therapies |
| Amount | £500,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | Wellcome trust infectious and immunity PhD programme, Cambridge - Matthew Reeves |
| Amount | £150,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Title | ACTIVITY-DEPENDENT GENE THERAPY FOR NEUROLOGICAL DISORDERS |
| Description | The invention provides expression vectors or vector systems comprising a polynucleotide sequence encoding a polypeptide, wherein the gene is operably linked to a neuronal activity-dependent promoter suitable to drive expression of the gene product in a subject's neural cells. The features of the expression vectors combine to advantageously improve the treatment of a neurological disorder associated with neuronal hyperexcitability in a subject. The invention also provides the expression vectors or vector systems for use in related methods of treatment, as well as viral particles, cells, kits and methods using the expression vectors or vector systems. |
| IP Reference | WO2021191474 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | none as yet |
| Title | DIAGNOSTIC TEST |
| Description | The invention relates to methods and kits for assessing the risk of spontaneous preterm birth in a pregnant female, especially early in pregnancy, by identifying markers of cervical immune competence. |
| IP Reference | WO2020074880 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Still in development |